



Tassilo Leo Alexander Wachsmann

Postdoctoral Scholar, Bioengineering

Bio

STANFORD ADVISORS

- Stanley Qi, Postdoctoral Faculty Sponsor

Publications

PUBLICATIONS

- **Durable epigenetic silencing with a TALE-based editor.** *Nature biotechnology*
Wachsmann, T. L., Qi, L. S.
2025
- **CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome** *TRENDS IN CANCER*
Wachsmann, T. L. A., Qi, L. S.
2025; 11 (10): 979-992
- **DNA-demethylation by DAC induces MAGE expression and MAGE-specific T cell reactivity against tumors but also healthy cell subsets** *MOLECULAR THERAPY ONCOLOGY*
de Rooij, M. A. J., Meeuwssen, M. H., Wouters, A. K., Remst, D. F. G., Hagedoorn, R. S., van der Steen, D. M., Verdegaal, E. M. E., Wachsmann, T. L. A., Falkenburg, J., Heemskerk, M. H. M.
2025; 33 (3): 201018
- **CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome.** *Trends in cancer*
Wachsmann, T. L., Qi, L. S.
2025
- **CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cells.** *Molecular therapy : the journal of the American Society of Gene Therapy*
Wachsmann, T. L., Poortvliet, T., Meeuwssen, M. H., Remst, D. F., Toes, M. F., Wouters, A. K., Hagedoorn, R. S., Falkenburg, J. H., Heemskerk, M. H.
2025
- **Targeting epigenetic regulation and post-translational modification with 5-Aza-2' deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapy** *JOURNAL FOR IMMUNOTHERAPY OF CANCER*
Kroonen, J. S., Wouters, A. K., de Graaf, I. J., Remst, D. F. G., Kumar, S., Wachsmann, T. L. A., Teunisse, A. S., Roelands, J. P., de Miranda, N. C., Griffioen, M., Heemskerk, M. H. M., Versteeg, A. C. O.
2024; 12 (9)
- **Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myeloma** *BLOOD ADVANCES*
Wachsmann, T. L. A., Meeuwssen, M. H., Remst, D. F. G., Buchner, K., Wouters, A. K., Hagedoorn, R. S., Falkenburg, J., Heemskerk, M. H. M.
2023; 7 (20): 6178-6183
- **High-affinity CD8 variants enhance the sensitivity of pMHC^{i> via} low TCRs** *JOURNAL OF BIOLOGICAL CHEMISTRY*

- Knezevic, L., Wachsmann, T. L. A., Francis, O., Dockree, T., Bridgeman, J. S., Wouters, A., de Wet, B., Cole, D. K., Clement, M., McLaren, J. E., Gostick, E., Ladell, K., Llewellyn-Lacey, et al
2023; 299 (8): 104981
- **PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer** *FRONTIERS IN IMMUNOLOGY*
van Amerongen, R. A., Tuit, S., Wouters, A. K., van de Meent, M., Siekman, S. L., Meeuwssen, M. H., Wachsmann, T. L. A., Remst, D. F. G., Hagedoorn, R. S., van der Steen, D. M., de Ru, A. H., Verdegaal, E. M. E., van Veelen, et al
2023; 14: 1121973
 - **Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain** *JOURNAL OF HEMATOLOGY & ONCOLOGY*
Meeuwssen, M. H., Wouters, A. K., Wachsmann, T. L. A., Hagedoorn, R. S., Kester, M. G. D., Remst, D. F. G., van der Steen, D. M., de Ru, A. H., van Hees, E. P., Kremer, M., Griffioen, M., van Veelen, P. A., Falkenburg, et al
2023; 16 (1): 16
 - **Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure** *ONCOIMMUNOLOGY*
Wachsmann, T. L. A., Wouters, A. K., Remst, D. F. G., Hagedoorn, R. S., Meeuwssen, M. H., van Diest, E., Leusen, J., Kuball, J., Falkenburg, J., Heemskerk, M. H. M.
2022; 11 (1): 2033528
 - **A library of cancer testis specific T cell receptors for T cell receptor gene therapy** *MOLECULAR THERAPY ONCOLYTICS*
de Rooij, M. A. J., Remst, D. F. G., van der Steen, D. M., Wouters, A. K., Hagedoorn, R. S., Kester, M. G. D., Meeuwssen, M. H., Wachsmann, T. L. A., de Ru, A. H., van Veelen, P. A., Verdegaal, E. M. E., Falkenburg, J., Heemskerk, et al
2023; 28: 1-14
 - **T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion** *JOURNAL FOR IMMUNOTHERAPY OF CANCER*
Morton, L. T., Wachsmann, T. L. A., Meeuwssen, M. H., Wouters, A. K., Remst, D. F. G., van Loenen, M. M., Falkenburg, J., Heemskerk, M. H. M.
2022; 10 (3)
 - **An HLA-A*11:01-Binding Neoantigen from Mutated NPM1 as Target for TCR Gene Therapy in AML** *CANCERS*
van der Lee, D. I., Koutsoumpli, G., Reijmers, R. M., Honders, M., de Jong, R. C. M., Remst, D. F. G., Wachsmann, T. L. A., Hagedoorn, R. S., Franken, K. C., Kester, M. G. D., Harber, K. J., Roelofsen, L. M., Schouten, et al
2021; 13 (21)
 - **Protein kinase A regulates inflammatory pain sensitization by modulating HCN2 channel activity in nociceptive sensory neurons** *PAIN*
Herrmann, S., Rajab, H., Christ, I., Schirdewahn, C., Hoefler, D., Fischer, M. J. M., Bruno, A., Fenske, S., Gruner, C., Kramer, F., Wachsmann, T., Wahl-Schott, C., Stieber, et al
2017; 158 (10): 2012-2024